Guaifenesin

Generic Name: Guaifenesin

Brand Names: Broncotron, Bronkaid, Cheracol D, Cheratussin, Cheratussin Dac, Codar Gf, Coricidin Hbp Chest Congestion, DM, Deconex, Delsym Cough Plus Chest Congestion DM, Despec Reformulated Jun 2008, Diabetic Tussin DM, Diabetic Tussin EX, Diphen, Entex Lq, Entex T, G-zyncof, Gilphex, M-clear Wc, Mar-cof Cg, Mucinex, Mucinex Children's Cough, Mucinex Cough, Mucinex D, Mucinex DM, Mucinex Stuffy Nose & Cold, Ninjacof Xg, Obredon, Pediacare Children's Cough and Congestion, Refenesen, Refenesen PE, Rescon-GG, Robafen, Robafen DM, Robitussin Chest Congestion, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Safetussin DM, Scot-tussin, Scot-tussin DM, Siltussin, Tusnel C, Tusnel Diabetic

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₄O_₄

CAS Number: 93-14-1

Unique Ingredient Identifier: 495W7451VQ

Background: Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant . Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and col...

Indication: Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold, bronchitis, and/or other breathing illnesses .

Associated Conditions: Allergic Reaction, Allergy to Tree Pollen, Asthma, Asthma, Allergic, Bronchial Asthma, Bronchitis, Bronchospasm, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Flu caused by Influenza, Drug Allergy, Emphysema, Fever, Flu caused by Influenza, Food Allergy, Headache, House dust allergy, Irritative cough, Laryngitis, Nasal Congestion, Nasal Congestion caused by Common Cold, Phlegm, Productive cough, Rash, Rhinorrhoea, Sneezing, Sore Throat, Tracheitis, Urticaria, Whooping Cough, Acute Rhinitis, Chest congestion, Chills occurring with fever, Dry cough, Excess mucus or phlegm, Mild to moderate pain, Minor aches and pains

Associated Therapies: Airway secretion clearance therapy, Expectorant

Clinical Trials

A Non-Interventional Safety Study of Balsamic Bactrim

Completed

Conditions: Bronchitis

Interventions: Drug: Guaifenesin
Drug: Sulfamethoxazole
Drug: Trimethoprim

First Posted Date: 2016-09-16

Last Posted Date: 2017-11-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT02902640

Locations: 🇵🇪
Clinica San Borja; Instituto de Enfermedades Respiratorias EFEH, Lima, Peru
🇵🇪
Clinica de Especialidades Medicas, Lima, Peru
🇵🇪
Centro de Investigaciones Medicas/Hospital Maria Auxiliadora, San Juan de Miraflores, Peru

and more 1 locations

A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis

Completed

Conditions: Bronchitis

Interventions: Drug: Guaifenesin
Drug: Sulfamethoxazole
Drug: Trimethoprim

First Posted Date: 2016-08-26

Last Posted Date: 2019-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 51

Registration Number: NCT02879981

Locations: 🇵🇪
Hospital Emergencias Pediatricas; Unidad de Investigación Pediátrica, La Victoria, Peru
🇵🇪
Clínica Anglo Americana-CENTRO DE INVESTIGACION PEDIATRIA CAA, San Isidro, Peru
🇵🇪
Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru

Exploratory Efficacy Study of Guaifenesin in Upper Back Pain

Not Applicable

Completed

Conditions: Upper Back Pain

Interventions: Drug: Placebo
Drug: Guaifenesin

First Posted Date: 2012-03-26

Last Posted Date: 2014-06-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 78

Registration Number: NCT01562548

Locations: 🇺🇸
Radiant Research, Inc. - TX, San Antonio, Texas, United States
🇺🇸
Med Investigations, Fair Oaks, California, United States
🇺🇸
J. Lewis Research, Salt Lake City, Utah, United States

and more 2 locations

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

Phase 2

Completed

Conditions: Acute Upper Respiratory Tract Infection

Interventions: Drug: Immediate-release Guaifenesin
Drug: Mucinex
Drug: Placebo

First Posted Date: 2012-02-22

Last Posted Date: 2013-11-14

Lead Sponsor: Reckitt Benckiser LLC

Target Recruit Count: 2810

Registration Number: NCT01537081

Locations: 🇺🇸
Reckitt Benckiser Study Site, Spokane, Washington, United States

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

Phase 2

Completed

Conditions: Chronic Rhinitis

Interventions: Drug: Placebo
Drug: Guaifenesin

First Posted Date: 2011-06-02

Last Posted Date: 2020-04-24

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 30

Registration Number: NCT01364467

Locations: 🇺🇸
Virginia Commonwealth University Children's Hospital of Richmond, Children's Pavilion & Nelson Clinic, Richmond, Virginia, United States

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Phase 4

Completed

Conditions: Acute Upper Respiratory Track Infection

Interventions: Device: Placebo
Drug: Guaifenesin

First Posted Date: 2010-09-15

Last Posted Date: 2020-12-30

Lead Sponsor: Reckitt Benckiser Inc.

Target Recruit Count: 1179

Registration Number: NCT01202279

Locations: 🇺🇸
Coastal Connecticut Research, LLC, 342 Montauk Avenue, New London, Connecticut, United States
🇺🇸
Clinical Associates Research, 750 Main Street, Suite 310, Reisterstown, Maryland, United States
🇺🇸
Clinical Research Advantage, Inc., Mesa, Arizona, United States

and more 21 locations

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

Phase 2

Completed

Conditions: Acute Respiratory Infection

Interventions: Drug: Mucinex
Drug: Placebo

First Posted Date: 2010-05-03

Last Posted Date: 2018-09-19

Lead Sponsor: Reckitt Benckiser LLC

Target Recruit Count: 38

Registration Number: NCT01114581

Locations: 🇺🇸
Center for Environmental Medicine, Asthma, and Lung Biology, Chapel Hill, North Carolina, United States

Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections

Not Applicable

Completed

Conditions: Infection

Interventions: Other: Buckwheat Honey
Drug: Placebo
Drug: Guaifenesin

First Posted Date: 2010-02-04

Last Posted Date: 2013-02-25

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 265

Registration Number: NCT01062256

Locations: 🇺🇸
Pfizer Investigational Site, Lexington, Kentucky, United States

Treatment of Acute Sinusitis

Phase 4

Completed

Conditions: Acute Respiratory Infections
Acute Rhinosinusitis

Interventions: Drug: Acetaminophen
Drug: Amoxicillin
Drug: Dextromethorphan hydrobromide with guaifenesin
Drug: Guaifenesin
Drug: Pseudoephedrine Sustained Action
Drug: Saline spray (0.65%)

First Posted Date: 2006-09-18

Last Posted Date: 2012-12-28

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 172

Registration Number: NCT00377403

Locations: 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States

Preventing Frequent Sinus Infections in HIV-Infected Patients

Phase 2

Withdrawn

Conditions: HIV Infections
Sinusitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00000752

Locations: 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States
🇺🇸
Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy